Mizoguchi H, O'Shea J J, Longo D L, Loeffler C M, McVicar D W, Ochoa A C
Biological Response Modifiers Program, National Cancer Institute, Frederick Cancer Research and Development Center, MD 21702.
Science. 1992 Dec 11;258(5089):1795-8. doi: 10.1126/science.1465616.
Impaired immune responses occur frequently in cancer patients or in tumor-bearing mice, but the mechanisms of the tumor-induced immune defects remain poorly understood. In an in vivo murine colon carcinoma model (MCA-38), animals bearing a tumor longer than 26 days develop CD8+ T cells with impaired cytotoxic function, decreased expression of the tumor necrosis factor-alpha and granzyme B genes, and decreased ability to mediate an antitumor response in vivo. T lymphocytes from tumor-bearing mice expressed T cell antigen receptors that contained low amounts of CD3 gamma and completely lacked CD3 zeta, which was replaced by the Fc epsilon gamma-chain. Expression of the tyrosine kinases p56lck and p59fyn was also reduced. These changes could be the basis of immune defects in tumor-bearing hosts.
免疫反应受损在癌症患者或荷瘤小鼠中经常出现,但肿瘤诱导的免疫缺陷机制仍知之甚少。在体内小鼠结肠癌模型(MCA-38)中,携带肿瘤超过26天的动物会产生细胞毒性功能受损的CD8+ T细胞,肿瘤坏死因子-α和颗粒酶B基因的表达降低,以及在体内介导抗肿瘤反应的能力下降。荷瘤小鼠的T淋巴细胞表达的T细胞抗原受体含有少量的CD3γ,并且完全缺乏CD3ζ,后者被Fcεγ链所取代。酪氨酸激酶p56lck和p59fyn的表达也降低。这些变化可能是荷瘤宿主免疫缺陷的基础。